Flagler Station — the Florida East Coast corridor in Medley, with direct access to the Homestead Extension of the Turnpike and the FEC intermodal rail yard — keeps an OTC drug compliance lawyer busier than almost anywhere in America. Flagler Station in Medley is among the largest business parks in the southeastern United States, a rail-served logistics campus where third-party warehouses handle other companies’ FDA-regulated freight at enormous volume. When FDA or CBP flags a shipment bound for a Flagler Station warehouse, the importer, the 3PL and the consignee all feel it at once — racking space fills, cold chains tick, and delivery windows collapse. Because so much of the park’s throughput is food, supplements and OTC products moving under tight delivery contracts, admissibility problems here become commercial emergencies within hours.
Quick answer
OTC drugs are lawful without individual approval only when they stay inside their monograph — the right ingredients, doses, indications and Drug Facts labeling — made in registered, listed, cGMP-compliant facilities. Step outside the monograph, or import from an unregistered plant, and the product is an unapproved new drug.
Why this matters now
OTC enforcement is unforgiving because the standards are written down: a monograph deviation is not a judgment call FDA has to argue, it is a checkbox. Unapproved-drug status invalidates inventory wholesale, import alerts on OTC categories persist for years, and cGMP failures at a supplier can cut off a product line overnight.
The rules in plain terms
Most over-the-counter drugs reach market through the OTC monograph system: FDA’s category-by-category rulebooks (sunscreens, antacids, hand sanitizers, analgesics, and dozens more) fixing which active ingredients, strengths, indications and label statements are permitted. A product matching its monograph needs no application; one deviating from it — a novel ingredient, an unlisted claim — is an unapproved new drug, full stop.
The operational regime is drug-grade: facility registration and drug listing (with NDC numbers), cGMP manufacturing compliance, the standardized Drug Facts label, and — since the CARES Act reformed the monograph system — OMUFA user fees for manufacturers. Foreign facilities need U.S. agents and face FDA inspection like domestic ones.
Import screening is where OTC compliance gets tested for Miami’s trade: entries from unregistered facilities, products with unlisted formulations, sunscreen and sanitizer shipments with monograph deviations, and cosmetics making drug claims all show up as holds, detentions and import-alert candidates. The hand-sanitizer era put entire foreign facility rosters on alert lists — many remain there.
How the process works
- Monograph analysis: does each formulation, dose and claim fit its monograph — and what changes if not
- Registration and listing compliance for every facility and product, with NDC and renewal management
- Drug Facts labeling and claims review, including the cosmetic/drug combination products Miami imports heavily
- Import compliance: supplier facility verification, entry data, and detention response for flagged entries
- cGMP and inspection readiness — 483 responses, warning-letter strategy and corrective-action programs
Serving Flagler Station from Brickell
The work around Flagler Station — third-party logistics, perishable food distribution, pharmaceutical and OTC wholesale, e-commerce fulfillment, consolidated freight — is FDA-regulated at nearly every turn, and matters here move on the Florida East Coast corridor in Medley, with direct access to the Homestead Extension of the Turnpike and the FEC intermodal rail yard. Garg Law's Miami office is at 1221 Brickell Avenue, and the practice was built for exactly this market: founder Shelly Garg spent years counseling importers at the world's largest dedicated international trade law firm before opening her own, and works at the crossroads of FDA and CBP compliance for foreign and domestic companies across the food, beverage, supplement, cosmetics, OTC drug and medical device industries.
Best practices — and common mistakes
- Marketing a “cosmetic” with drug claims instead of running it through the monograph analysis
- Importing from facilities that never registered or listed — the entry screen catches it
- Tweaking a monograph formulation for marketing differentiation and creating an unapproved new drug
- Drug Facts labels that omit or reorder required elements
- Assuming legacy hand-sanitizer-era suppliers came off import alerts — many did not
Frequently asked questions
Do OTC drugs need FDA approval?
Not individually — if they conform to the applicable OTC monograph in ingredients, strength, indications and labeling, and are made in registered, listed, cGMP-compliant facilities. Products outside a monograph need an approved application; selling them without one is marketing an unapproved new drug.
What is a Drug Facts label and is it mandatory?
Yes — the standardized panel (active ingredients, purposes, uses, warnings, directions, inactive ingredients) with prescribed content and order for OTC drugs. Formatting deviations are labeling violations FDA and the import screen both flag.
Is my product a cosmetic or an OTC drug?
Claims decide: a moisturizer is a cosmetic; a moisturizer “with SPF” is a drug (sunscreen monograph); an antiperspirant is a drug while a deodorant is a cosmetic. Combination cosmetic-drugs must satisfy both regimes — a constant issue in Miami’s beauty import trade.
Why are OTC imports from certain factories always detained?
Import alerts. Facilities with cGMP findings, refused inspections or violative samples get listed for detention without physical examination — the sanitizer boom added hundreds. Sourcing decisions should check alert lists first; removal petitions exist but take documented time.
What are OMUFA fees and who pays them?
The OTC Monograph User Fee program funds FDA’s modernized monograph system through annual facility fees on OTC drug manufacturers. Unpaid fees have consequences — including products from unpaid facilities being deemed misbranded. Fee status belongs on the compliance calendar like registration renewals.